The publisher explores Vertex’s prescription pharmaceutical performance and outlook over 2019-29.
Snapshot
Model updates (4 November 2020)
Model updates (31 July 2020)
Model updates (29 April 2020)
Model updates (30 January 2020)
Snapshot
- Overview - Vertex is making impressive progress with its newly launched and late-stage investigational cystic fibrosis products.
- Key themes - [1] Vertex is set for continued global cystic fibrosis market domination with its commercial and pipeline portfolios [2] Vertex’s cystic fibrosis franchise faces no short-to-medium-term competitive threats [3] Vertex is holding a hard line against ongoing pricing criticisms in the US and five major European markets.
Model updates (4 November 2020)
- Trikafta forecast adjusted lower due to sales trends.
Model updates (31 July 2020)
- Trikafta forecast adjusted higher due to continued robust launch in the US; EU and RoW forecasts adjusted higher due to assumed faster launch in those regions upon approval
- Symdeko forecast adjusted lower in the US due to the cannibalization from Trikafta.
Model updates (29 April 2020)
- Trikafta forecast adjusted significantly higher due to faster than expected uptake
- Orkambi forecast adjusted lower due to accelerated pace of cannibalization from Trikafta
- Symdeko forecast adjusted lower due to accelerated pace of cannibalization from Trikafta.
Model updates (30 January 2020)
- Trikafta forecast adjusted higher due to stronger than expected launch
- Orkambi forecast adjusted lower due to pace of cannibalization from Trikafta.
Table of Contents
Company Background
Recent Earnings Review
Company Forecast
Company Profile
Clinical Trial Overview
